Collagen-based cell regeneration: What makes Orthocell’s scaffold technology different from other collagen therapies?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Collagen-based cell regeneration: What makes Orthocell’s scaffold technology different from other collagen therapies?
Released on: December 08, 2015. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Paul Anderson, Managing Director to Orthocell, reveals the unique technology behind their versatile therapy for tendon and soft-tissue injuries.
  • Summary
  • Transcript
  • Participants
  • Company
Paul Anderson, Managing Director to Orthocell, reveals the unique technology behind their versatile therapy for tendon and soft-tissue injuries.
Paul Anderson, Managing Director to Orthocell, reveals the unique technology behind their versatile therapy for tendon and soft-tissue injuries.
Paul has over 14 years experience in the medical device and cellular therapeutic fields with expertise in bridging the gap between research and clinical practice in the development of emerging medical technologies. This encompasses applying the regulatory framework to the product and the accompanying ‘grey area’ interpretation, rebating pathways, marketing, sales, developing orthopaedic relationships, strategic and financial planning. Paul has a strong track record with his previous board position with Verigen Australia Pty Ltd a human cell therapies company.
OrthoCell
Orthocell is a Biotherapeutic company dedicated to improvement of the lives of people suffering from soft tissue injuries by providing innovative approaches to the regeneration of damaged tendon, cartilage and ligament tissue.